Boehringer races to catch up in NASH through Yuhan deal

Boehringer is playing catch up in NASH through a preclinical deal with Yuhan that doubles its programs in the indication from one to two and marks its entry into combining therapeutic MOAs -- a strategy the field has pegged as the best bet for attacking the disease.

On Monday, Boehringer Ingelheim GmbH (Ingelheim, Germany) said it is licensing a preclinical fusion protein from

Read the full 622 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE